A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile * Male or female between 18 and 70 years, inclusive, at time of Screening. * Chronic HCV-infection prior to study enrollment. * Screening laboratory result indicating HCV genotype 1-infection. * Compensated cirrhosis defined as a Child-Pugh Score of less than or equal to 6 at Screening * Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.

* Significant liver disease with any cause other than HCV as the primary cause * Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) at screening. * Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir and boceprevir. * Any current or past clinical evidence of Child-Pugh B or C Classification or clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy. * A positive screening ultrasound for hepatocellular carcinoma (HCC) confirmed with a subsequent CT Scan or MRI during the screening period.